Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 5 versus H R 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 5 versus H R 50.
ANDROID 5 vs H.R.-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Selective estrogen receptor degrader (SERD); binds to estrogen receptor alpha, inducing degradation and inhibiting estrogen signaling.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
12.5 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Terminal elimination half-life is 4-6 hours in adults with normal renal function; prolonged to 10-12 hours in moderate renal impairment (CrCl <50 mL/min).
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Renal excretion of unchanged drug accounts for 60-70%; biliary/fecal excretion accounts for 20-30%; <10% metabolized.
Category C
Category C
Androgen
Androgen